The abstract is read at the publisher; the summary is JClub's.
In kidney-specific mouse models of Birt-Hogg-Dubé and Tuberous Sclerosis, mTORC1 hyperactivation is a key driver of cystogenesis and tumorigenesis, while TFEB/TFE3 activation accelerates pathology.
- Why it matters: The work addresses whether TFEB/TFE3 promote kidney cancer mainly by inducing mTORC1 or through mTORC1-independent programs in inherited cancer syndromes.
- What they did: Kidney-specific conditional knockouts were created: Depdc5-KO (mTORC1 hyperactivation with TFEB/TFE3 inhibition), RagC-KO (TFEB/TFE3 constitutively active with partially inhibited mTORC1), and Flcn/RagC double KO to test effects of RagC-driven mTORC1 inhibition.
- The result: Model comparisons show mTORC1 hyperactivation drives disease, and TFEB/TFE3 constitutive activation further enhances and accelerates pathology via a transcriptional program integrating metabolic and stress-response pathways.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.